Cui-Rong Zhao
Overview
Explore the profile of Cui-Rong Zhao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
84
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang J, Wang X, Li J, Zhao C, Liu M, Ye B
Front Psychol
. 2021 Dec;
12:770681.
PMID: 34925172
Teacher's unethical professional behaviors affect students' physical and mental health. Prevention should start with student teachers, but empirical research is lacking in China. This study surveyed over 2,000 student teachers...
2.
Lu Y, Zhao C, Wang R, Li W, Qu X
Biomed Pharmacother
. 2015 Feb;
69:255-9.
PMID: 25661367
HL-40, N-(4-(1-(4-chlorine indazole)) phenyl)-N-(4-chloro-3-three fluorine methyl phenyl) urea, is a novel diarylurea derivative. In this study, we investigated the kinases activities and binding constants, pharmacokinetics of HL-40, and then evaluated...
3.
Chu J, Zhao C, Song Z, Wang R, Qin Y, Li W, et al.
Biomed Pharmacother
. 2014 Mar;
68(3):335-41.
PMID: 24581722
Purpose: 1082-39, an analogue of sorafenib, is a derivative of indazole diarylurea. We evaluated the activity of 1082-39 against human cancer cell growth. Its effects and mechanisms of action were...
4.
Zhao C, Wang R, Li G, Xue X, Sun C, Qu X, et al.
Bioorg Med Chem Lett
. 2013 Mar;
23(7):1989-92.
PMID: 23454017
New series of indazole based diarylureas were synthesized and their anticancer activity against cancer cells H460, A549, OS-RC-2, HT-29, Lovo, HepG2, Bel-7402, SGC-7901 and MDA-MB-231 were examined. These derivatives of...
5.
Yue B, Zhao C, Xu H, Li Y, Cheng Y, Ke H, et al.
Biochim Biophys Acta
. 2012 Oct;
1830(1):2194-203.
PMID: 23085067
Background: Riccardin D-26, a synthesized macrocyclic bisbibenzyl compound, might possess anti-cancer properties. We aimed to evaluate the efficacy of Riccardin D-26 as a candidate compound for treatment of cancers with...
6.
Yue B, Zhang Y, Xu H, Zhao C, Li Y, Qin Y, et al.
Cancer Lett
. 2012 Sep;
328(1):104-13.
PMID: 22995069
Riccardin D-26 is a synthesized macrocyclic bisbibenzyl compound. We investigated the effect of Riccardin D-26 on human hepatocellular carcinomas. Riccardin D-26 possessed stronger activity against SMMC-7721 cells than human normal...
7.
Liu H, Gao Z, Cui S, Sun D, Wang Y, Zhao C, et al.
PLoS One
. 2012 Mar;
7(3):e33243.
PMID: 22432006
Background: Mutation of tumor suppressor gene, adenomatous polyposis coli (APC), is the primary molecular event in the development of most intestinal carcinomas. Animal model with APC gene mutation is an...
8.
Xue X, Sun D, Sun C, Liu H, Yue B, Zhao C, et al.
Lung Cancer
. 2012 Jan;
76(3):300-8.
PMID: 22261315
Riccardin D is a macrocyclic bisbibenzyl compound extracted from liverwort plant Dumortiera hirsuta. Our previous study showed that riccardin D induced apoptosis of human leukemia cells by targeting DNA topoisomerase...
9.
Sun C, Zhang Y, Xue X, Cheng Y, Liu H, Zhao C, et al.
Eur J Pharmacol
. 2011 Jun;
667(1-3):136-43.
PMID: 21704029
Riccardin D is a novel macrocyclic bisbibenzyl compound extracted from Chinese liverwort plant Dumortiera hirsuta. Our previous studies showed that riccardin D is a DNA topo II inhibitor and has...
10.
Yue P, Gao Z, Xue X, Cui S, Zhao C, Yuan Y, et al.
Eur J Cancer
. 2011 Feb;
47(7):1115-24.
PMID: 21349701
Des-γ-carboxy prothrombin (DCP), an aberrant prothrombin produced by hepatocellular carcinoma (HCC) cells, has been shown to be associated with the biological malignant potential of HCC. The aim of this study...